At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BCTX BriaCell Therapeutics Corp.
Trading 05-20 15:23:23 EDT
3.86
+0.35
+9.83%
High3.97Low3.45Vol404.82K
Open3.53D1 Closing3.51Amplitude14.96%
Mkt Cap27.95MTradable Cap24.99MTotal Shares7.25M
T/O1.54MT/O Rate6.24%Tradable Shares6.48M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™
GlobeNewswire  ·  05-15
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™
BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer
GlobeNewswire  ·  05-14
BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer
BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
GlobeNewswire  ·  05-13
BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients
GlobeNewswire  ·  05-12
BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients
BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer
GlobeNewswire  ·  05-06
BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer
BriaCell Announces Six Clinical Data Presentations at ASCO 2026
GlobeNewswire  ·  04-27
BriaCell Announces Six Clinical Data Presentations at ASCO 2026
BriaCell presents anti-cancer activity of Bria-OTS
TIPRANKS  ·  04-21
BriaCell presents anti-cancer activity of Bria-OTS
BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting
GlobeNewswire  ·  04-20
BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting
BriaCell Therapeutics Reports Rising Losses and Funding Pressure
TIPRANKS  ·  04-01
BriaCell Therapeutics Reports Rising Losses and Funding Pressure
BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License
GlobeNewswire  ·  04-01
BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License
BriaCell to present four posters at the 2026 AACR
TIPRANKS  ·  03-18
BriaCell to present four posters at the 2026 AACR
BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference
GlobeNewswire  ·  03-18
BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference
BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting
GlobeNewswire  ·  03-10
BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting
BriaCell Shareholders Approve Auditors and Reelect Board
TIPRANKS  ·  03-10
BriaCell Shareholders Approve Auditors and Reelect Board
BriaCell Shareholders Overwhelmingly Back Board and Auditors at Annual Meeting
TIPRANKS  ·  03-06
BriaCell Shareholders Overwhelmingly Back Board and Auditors at Annual Meeting
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
GlobeNewswire  ·  03-06
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
BriaCell Restructures Soluble CD80 Program via BriaPro Deal
TIPRANKS  ·  02-21
BriaCell Restructures Soluble CD80 Program via BriaPro Deal
BriaPro to purchase BriaCell’s license to develop, commercialize sCD80
TIPRANKS  ·  02-19
BriaPro to purchase BriaCell’s license to develop, commercialize sCD80
BriaCell Therapeutics' Phase 3 Breast Cancer Treatment Trial Gets Fifth DSMB Recommendation to Continue
MT Newswires Live  ·  02-17
BriaCell Therapeutics' Phase 3 Breast Cancer Treatment Trial Gets Fifth DSMB Recommendation to Continue
BriaCell says patient images show regression, resolution of metastsized tumors
TIPRANKS  ·  01-28
BriaCell says patient images show regression, resolution of metastsized tumors

Introduction

Company Name.
BriaCell Therapeutics Corp.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Issue price:
--